Another study demonstrated that the COX-2-PGE2 pathway should be investigated as a target for primary non-responders to tumor necrosis factor (TNF) inhibitor therapy, as well as a prognostic biomarker for TNF inhibitor response in patients with ulcerative colitis [129]. The gene discussed is TNF; the disease is ulcerative colitis.